HopeStage
Back to all studies
RecruitingNCT06931080

EB-1020 for adults with ADHD: safety and effects

About this titleRead the official source — NCT06931080

Researchers are comparing EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg and placebo, tracking side effects to assess safety in adults with ADHD.

Medication studyAges 18–55Japan
The study in practice

Understand this study

What is this study about?

Researchers are comparing EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg and placebo, tracking side effects to assess safety in adults with ADHD.

Who could participate?

This study is for people with ADHD. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.

What will I do during this study?

Depending on your study group, you take EB-1020 (centanafadine) or a placebo (an inactive comparison treatment) as an oral capsule once daily for six weeks. The active-treatment groups receive different dose levels.

Study phase
Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: April 30, 2025
Recruitment status
Recruiting
Enrollment listed in the registry
630
Sponsor
Otsuka Pharmaceutical Co., Ltd.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Locations
Japan
Age range
From 18 Years to 55 Years
Official registry ID
NCT06931080
Official title
Show the full official title

A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Trial to Evaluate the Efficacy and Safety of EB-1020 Once Daily QD XR Capsules Administered Orally at Low or High Dose in Adults With Attention-deficit/Hyperactivity Disorder

Recruitment & locations

Currently recruiting

Tokyo

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

Researchers are comparing EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg and placebo, tracking side effects to assess safety in adults with ADHD.

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Co., Ltd., a pharmaceutical company.

Does this study involve medication?

Yes. The study involves medication, including EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg and Placebo.

Who can participate?

This study is for people with ADHD. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies